Glucosamine abrogates the acute phase of experimental autoimmune encephalomyelitis by induction of Th2 response

Journal of Immunology

Volumn 175, Issue 11, 2005, Pages 7202-7208

  Zhang, Guang Xian ^a   Yu, Shuo ^a   Gran, Bruno ^a   Rostami, Abdolmohamad ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSAMINE; GLUCOSE DERIVATIVE; GLYCOPROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 5; PROTEOGLYCAN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEMYELINATION; DRUG EFFICACY; FEMALE; GRAFT SURVIVAL; IMMUNE RESPONSE; IMMUNOREGULATION; IN VITRO STUDY; MOUSE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH2 CELL; TREATMENT OUTCOME;

EID: 28244432859     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.11.7202     Document Type: Article

References (44)

1. Steinman, L. 1999. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 24: 511-514.
2. Martin, R., and H. F. McFarland. 1995. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit. Rev. Clin. Lab. Sci. 32: 121-182.
3. Powell, M. B., D. Mitchell, J. Lederman, J. Buckmeier, S. S. Zamvil, M. Graham, N. H. Ruddle, and L. Steinman. 1990. Lymphotoxin and tumor necrosis factor-α production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int. Immunol. 2: 539-544.
4. Chitnis, T., and S. J. Khoury. 2003. Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis. Immunol. Res. 28: 223-239.
5. Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. McClanahan, R. A. Kastelein, and D. J. Cua. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201: 233-240.
6. Burkhart, C., G. Y. Liu, S. M. Anderton, B. Metzler, and D. C. Wraith. 1999. Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. Int. Immunol. 11: 1625-1634.
7. Bettelli, E., M. P. Das, E. D. Howard, H. L. Weiner, R. A. Sobel, and V. K. Kuchroo. 1998. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J. Immunol. 161: 3299-3306.
8. Felson, D. T., and T. E. McAlindon. 2000. Glucosamine and chondroitin for osteoarthritis: to recommend or not to recommend? Arthritis Care Res. 13: 179-182.
9. Reginster, J. Y., R. Deroisy, L. C. Rovati, R. L. Lee, E. Lejeune, O. Bruyere, G. Giacovelli, Y. Henrotin, J. E. Dacre, and C. Gossett. 2001. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebocontrolled clinical trial. Lancet 357: 251-256.
10. Shikhman, A. R., K. Kuhn, N. Alaaeddine, and M. Lotz. 2001. N-acetylglucosamine prevents IL-1α-mediated activation of human chondrocytes. J. Immunol. 166: 5155-5160.
11. Gouze, J. N., A. Bianchi, P. Becuwe, M. Dauca, P. Netter, J. Magdalou, B. Terlain, and K. Bordji. 2002. Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-κB pathway. FEBS Lett. 510: 166-170.
12. Forchhammer, L., M. Thorn, O. Met, M. Gad, M. S. Weidner, and M. H. Claesson. 2003. Immunobiological effects of glucosamine in vitro. Scand. J. Immunol 58: 404-411.
13. Ma, L., W. A. Rudert, J. Harnaha, M. Wright, J. Machen, R. Lakomy, S. Qian, L. Lu, P. D. Robbins, M. Trucco, and N. Giannoukakis. 2002. Immunosuppressive effects of glucosamine. J. Biol. Chem. 277: 39343-39349.
14. Benson, J. M., K. A. Campbell, Z. Guan, I. E. Gienapp, S. S. Stuckman, T. Forsthuber, and C. C. Whitacre. 2000. T-cell activation and receptor down-modulation precede deletion induced by mucosally administered antigen. J. Clin. Invest. 106: 1031-1038.
15. Zhang, G. X., B. Gran, S. Yu, J. Li, I. Siglienti, X. Chen, M. Kamoun, and A. Rostami. 2003. Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-β2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J. Immunol. 170: 2153-2160.
16. Aloisi, F., R. De Simone, S. Columba-Cabezas, G. Penna, and L. Adorini. 2000. Functional maturation of adult mouse resting microglia into an APC is promoted by granulocyte-macrophage colony-stimulating factor and interaction with Th1 cells. J. Immunol. 164: 1705-1712.
17. Muhl, H., and J. Pfeilschifter. 2003. Endothelial nitric oxide synthase: a determinant of TNFα production by human monocytes/macrophages. Biochem. Biophys. Res. Commun. 310: 677-680.
18. Rodriguez-Sinovas, A., D. Garcia-Dorado. P. Pina, M. Ruiz-Meana, and J. Soler-Soler. 2005, Effect of sarcolemmal rupture on myocardial electrical impedance during oxygen deprivation. Am. J. Physiol. 288: H1396-H1403.
19. Tallarida, R. J., A. Cowan, and R. B. Raffa. 2003. Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice. J. Pharmacol. Exp. Ther. 307: 699-704.
20. Suter, T., U. Malipiero, L. Otten, B. Ludewig, A. Muelethaler-Mottet, B. Mach, W. Reith, and A. Fontana. 2000. Dendritic cells and differential usage of the MHC class II transactivator promoters in the central nervous system in experimental autoimmune encephalitis. Eur. J. Immunol. 30: 794-802.
21. Fischer, F. R., Y. Luo, M. Luo, L. Santambrogio, and M. E. Dorf. 2001. RANTES-induced chemokine cascade in dendritic cells. J. Immunol. 167: 1637-1643.
22. Segal, B. M. 2003. Experimental autoimmune encephalomyelitis: cytokines, effector T cells, and antigen-presenting cells in a prototypical Th1-mediated autoimmune disease. Curr. Allergy Asthma Rep. 3: 86-93.
23. Miller, A. 1997. Current and investigational therapies used to alter the course of disease in multiple sclerosis. South Med. J. 90: 367-375.
24. Hafler, D. A., J. M. Slavik, D. E. Anderson, C. K. O'Connor, P. De Jager, and C. Baecher-Allan. 2005. Multiple sclerosis. Immunol. Rev. 204: 208-231.
25. Galetta, S. L., and C. Markowitz. 2005. US PDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles. CNS Drugs 19: 239-252.
26. Santambrogio, L., S. L. Belyanskaya, F. R. Fischer, B. Cipriani, C. F. Brosnan, P. Ricciardi-Castagnoli, L. J. Stern, J. L. Strominger, and R. Riese. 2001. Developmental plasticity of CNS microglia. Proc. Natl. Acad. Sci. USA 98: 6295-6300.
27. Suter, T., G. Biollaz, D. Gatto, L. Bernasconi, T. Herren, W. Reith, and A. Fontana. 2003. The brain as an immune privileged site: dendritic cells of the central nervous system inhibit T cell activation. Eur. J. Immunol. 33: 2998-3006.
28. Matyszak, M. K., S. Denis-Donini, S. Citterio, R. Longhi, F. Granucci, and P. Ricciardi-Castagnoli. 1999. Microglia induce myelin basic protein-specific T cell anergy or T cell activation, according to their state of activation. Eur. J. Immunol. 29: 3063-3076.
29. Olsson, T. 1995. Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology 45: Sl1-S12.
30. McDevitt, H. 2004. Specific antigen vaccination to treat autoimmune disease. Proc. Natl. Acad. Sci. USA 101(Suppl. 2): 14627-14630.
31. Weiner, H. L., A. Friedman, A. Miller, S. J. Khoury, A. al-Sabbagh, L. Santos, M. Sayegh, R. B. Nussenblatt, D. E. Trentham, and D. A. Hafler. 1994. Oral tolerance: immunologie mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol. 12: 809-837.
32. Cua, D. J., D. R. Hinton, and S. A. Stohlman. 1995. Self-antigen-induced Th2 responses in experimental allergic encephalomyelitis (EAE)-resistant mice: Th2-mediated suppression of autoimmune disease. J. Immunol. 155: 4052-4059.
33. Zhang, G. X., H. Xu, M. Kishi, D. Calida, and A. Rostami. 2002. The role of IL-12 in the induction of intravenous tolerance in experimental autoimmune encephalomyelitis. J. Immunol. 168: 2501-2507.
34. Zhang, G. X., S. Yu, Y. Li, E. S. Ventura, B. Gran, and A. Rostami. 2005. A paradoxical role of APCs in the induction of intravenous tolerance in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 161: 101-112.
35. Aggarwal, S., N. Ghilardi, M. H. Xie, F. J. De Sauvage, and A. L. Gurney. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278: 1910-1914.
36. Whitacre, C. C., F. Song, R. M. Wardrop III, K. Campbell, M. McClain, J. Benson, Z. Guan, and I. Gienapp. 2004. Regulation of autoreactive T cell function by oral tolerance to self-antigens. Ann. NY Acad. Sci. 1029: 172-179.
37. Youssef, S., O. Stuve, J. C. Patarroyo, P. J. Ruiz, J. L. Radosevich, E. M. Hur, M. Bravo, D. J. Mitchell, R. A. Sobel, L. Steinman, and S. S. Zamvil. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420: 78-84.
38. Soldan, S. S., A. I. Alvarez Retuerto, N. L. Sicotte, and R. R. Voskuhl. 2003. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J. Immunol. 171: 6267-6274.
39. Jung, T., J. P. Bews, K. H. Enssle, K. Wagner, C. Neumann, and C. H. Heusser. 1998. Detection of and discrimination between total and free human interleukin-4 and free soluble interleukin-4 receptor by ELISA. J. Immunol. Methods 217: 41-50.
40. Fukuda, K., Y. Fujitsu, N. Kumagai, and T. Nishida. 2002. Characterization of the interleukin-4 receptor complex in human corneal fibroblasts. Invest. Ophthalmol. Vis. Sci. 43: 183-188.
41. Coleman, J. W. 2001. Nitric oxide in immunity and inflammation. Int. Immunopharmacol. 1: 1397-1406.
42. Byrnes, A. A., J. C. McArthur, and C. L. Karp. 2002. Interferon-β therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann. Neurol. 51: 165-174.
43. Nagai, T., O. Devergne, T. F, Mueller, D. L. Perkins, J. M. van Seventer, and G. A. van Seventer. 2003. Timing of IFN-β exposure during human dendritic cell maturation and naive Th ceil stimulation has contrasting effects on Th1 subset generation: a role for IFN-β-mediated regulation of IL-12 family cytokines and IL-18 in naive Th cell differentiation. J. Immunol. 171: 5233-5243.
44. Ersoy, E., C. N. Kus, U. Sener, I. Coker. and Y. Zorlu. 2005. The effects of interferon-β on interleukin-10 in multiple sclerosis patients. Eur. J. Neurol. 12: 208-211.